CA-125 of 73 U/mL in Endometrioma: Impact on Management
A CA-125 level of 73 U/mL in a patient with an endometrioma should not alter the fundamental management plan, as current guidelines explicitly recommend against routine use of CA-125 for management decisions in endometriosis. 1
Guideline-Based Approach
The most recent and authoritative guidance from the ACR O-RADS US committee (2020) purposely did not advocate for routine use of serum markers in assessment based on lesion category 1. The committee specifically warns that an elevated CA-125 in a premenopausal patient with an intermediate-risk lesion and clinical features suspicious for endometriosis "may unnecessarily elevate the concern for malignancy" 1.
Why CA-125 Should Not Change Your Plan:
CA-125 elevation is expected with endometriomas: The level of 73 U/mL falls within the typical range for endometriomas, where mean levels of 50-61 U/mL are commonly observed 2, 3
Poor diagnostic specificity: While CA-125 correlates with disease severity (particularly deep infiltrating endometriosis and larger endometriomas), it has limited utility as a diagnostic marker, especially for mild-to-moderate disease 4
No impact on treatment efficacy: Historical ACOG guidelines confirm that no medical therapy has been proven to eradicate endometriotic lesions, and there is no evidence that CA-125 levels predict treatment response 4
Clinical Context for This Level
Your patient's CA-125 of 73 U/mL indicates:
Likely presence of an endometrioma ≥4 cm: Studies show CA-125 levels increase with cyst diameter, with mean levels of 53 U/mL for endometriomas ≥4 cm 5
Possible deep infiltrating disease: CA-125 ≥35 U/mL correlates with higher likelihood of DIE lesions (91.2% vs 76.2%) and intestinal involvement (63.2% vs 25.4%) 6
Not suggestive of malignancy: In the context of imaging-confirmed endometrioma in a premenopausal woman, this level does not raise malignancy concern
Management Algorithm
Base your management on:
- Clinical symptoms (dysmenorrhea, dyspareunia, pelvic pain severity)
- Imaging characteristics (O-RADS classification)
- Fertility goals
- Patient age and menopausal status
Not on CA-125 levels
Treatment Options Remain Unchanged:
- Medical management: GnRH agonists (≥3 months), danazol (≥6 months), oral contraceptives, or progestins for pain relief 4
- Surgical management: If symptoms persist, fertility is desired, or imaging suggests complexity
- Expectant management: If asymptomatic or minimal symptoms
Critical Caveat
The only scenario where CA-125 might influence management is if you're uncertain about the diagnosis between endometrioma versus other benign cysts. CA-125 >20 U/mL has excellent specificity (100%) for differentiating endometriomas from non-endometriotic benign cysts 5. However, if imaging already confirms endometrioma, this distinction is moot.
Do not use CA-125 to:
- Monitor treatment response
- Decide between medical versus surgical therapy
- Determine timing of intervention
- Assess recurrence risk
The elevated level simply confirms what imaging likely already demonstrated—the presence of endometriosis—but adds no actionable information to your management strategy.